Numerous other agents such as Bcl-2 antagonists, Btk inhibitors and dihydroartemisinin have shown promise in reducing levels of circulating Type I IFN in laboratory and animal models of lupus. This evidence concerns the gene BCL2 and systemic lupus erythematosus.